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Background: NFATc1 is a transcription factor activated by the
calcium/calcineurin pathway, which regulates several physiolog-
ical processes. Evidence has also shown a role for NFAT transcrip-
tions factors in oncogenesis. BRG1 and BRM are chromatin-
remodelling genes that are also regulated by calcium homoeosta-
sis. Diminished expression of BRG1 is associated with poor prog-
nosis in breast cancer, non-small-cell lung cancer, colorectal
cancer, and prostate cancer. To understand the biological rela-
tionship between these two pathways, we examined the expres-
sion pattern of NFATc1, BRG1, and BRM in invasive breast cancer.
Methods: Paraffin blocks of 150 cases of invasive breast cancer
were retrieved from Kaiser Permanente Medical Centre database.
Monoclonal antibodies against NFATc1, BRG1, and BRM were
used, and expression pattern was determined as no expression,
weak (1+ staining intensity), moderate (2+), and high expression
(3+). Pearson Chi-Squared test was used for statistical analysis.
Findings: NFATc1 was expressed in approximately 22% of the
150 cases of invasive breast cancer, whereas BRG1 was expressed
in 56.7% and BRM in 52%. Both nuclear and cytoplasmic expres-
sion of NFATc1 was detected, with nuclear expression as the pre-
dominant feature. BRM1/BRM are predominantly expressed in the
nucleus. Most cases expressing NFATc1 showed 2+ moderate
intensity expression patterns. Statistical analysis showed that
expression of NFATc1 was highly correlated with the expression
of both BRG1 and BRM.
Interpretation: Our preliminary data shows that NFATc1 is
expressed in a subset of BRG1/BRM-positive invasive breast can-
cers. This correlation of two calcium homoeostasis-regulated
pathways provides insight into the oncogenesis of breast cancer.
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Background: Invasive fungal infections (IFI) vary considerably
worldwide and it is difficult to make a definitive microbiological
diagnosis. Therefore, we investigated the epidemiology of IFI by
use of panfungal PCR (PFPCR), during febrile episodes in patients
with haematological malignancies at Kidwai Memorial Institute
of Oncology – a Regional Cancer Centre for diagnosis, treatment,
and research on cancer in South India.
Methods: Over a period of 11 months, 160 febrile episodes in
125 patients with haematological malignancies undergoing treat-
ment at our institute were prospectively investigated for IFI. Fun-
gal DNA was extracted from whole blood, amplified by PFPCR
using primers against the conserved regions of fungal 18SrRNA
gene sequences, and speciated by dot-blot hybridisation.
Findings: 30 of the febrile episodes (19%) were positive for fun-
gal DNA, only two of which yielded fungal growth from blood. Fre-
quencies of proven, probable, possible IFI, and fungal DNAemia
without radiological or culture evidence were 1.3%, 0.63%, 5%,
and 12%, respectively. Infection by Candida species predominated
(22 of 30 [73%]), of which the majority were C.albicans [16 of 22
[73%]). Five of 22 (23%) were due to C.tropicalis. Infection due to
Aspergillus was rare (3%). Using EORTC criteria for defined IFI,
the sensitivity, specificity, positive, and negative predictive values
of PFPCR were 100%, 87%, 37%, and 100%, respectively.
Interpretation: Although fungal-DNA-positive febrile episodes
were seen in 19% of patients, the prevalence of IFI using the
revised EORTC criteria was 6.9%. Nevertheless, the high negative
predictive value of PFPCR makes it a reliable test that could allow
IFI to be excluded in patients with febrile neutropenia, and would
render unwarranted empirical antifungal treatment unnecessary.
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Background: We evaluated adverse events of nimotuzumab
combined with chemotherapy, radiotherapy, or chemoradiother-
apy in treatment of advanced carcinomas.
Methods: We reviewed 835 patients with pathologically diag-
nosed malignant tumours of stage II–IV with metastasis, who
were treated from January, 2010, until October, 2010, at 40 hospi-
tals nationwide, by nimotuzumab combined with radiotherapy,
chemotherapy, or chemoradiotherapy. Generally, patients were
receiving a dose of 45–72 Gy radiotherapy. Patients who were also
receiving chemotherapy were mainly receiving platinum agents.
All patients were receiving 100–200 mg nimotuzumab once a
week at the same time as the other therapies.
Findings: Medical records could be analysed in 792 cases, of
which 241 were nasopharyngeal cancer (28.86%); the next most
common type of malignancy was head and neck cancer (153 cases
[18.32%]). Patients were 37–75 years with a median age of 63.
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